Health-related quality of life (HRQoL) results from the AURELIA trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum-resistant recurrent ovarian cancer (OC)

被引：0
|
作者：
Hilpert, F. [1 ]
Wimberger, P. [2 ]
Sehouli, J. [3 ]
Reuss, A. [4 ]
Harter, P. [5 ]
Hils, R. [6 ]
De Gregorio, N. [7 ]
Lueck, H. -J. [8 ]
Gerber, B. [9 ]
Fehm, T. [10 ]
Hanker, L. [11 ]
Uleer, C. [12 ]
Burges, A. [13 ]
Kosse, J. [14 ]
Thill, M. [15 ]
Beckmann, M. [16 ]
Scharf, J. -P. [17 ]
Meier, W. [18 ]
Gebauer, G. [19 ]
Pujade-Lauraine, E. [20 ]
机构：
[1] UKSH Campus Kiel, Klin Gynakol & Geburtshilfe, Kiel, Germany
[2] Univ Klinikum Carl Gustav Carus, Klin & Poliklin Frauenheilkunde & Geburtshilfe, Dresden, Germany
[3] Charite, Klin Gynakol, Berlin, Germany
[4] Univ Marburg, KKS, Marburg, Germany
[5] Kliniken Essen Mitte, Essen, Germany
[6] HSK, Wiesbaden, Germany
[7] Univ Ulm Klinikum, Ulm, Germany
[8] Gynakol Onkol Schwerpunktpraxis, Hannover, Germany
[9] Klinikum Sudstadt, Univ Frauenklin, Rostock, Germany
[10] Univ Klinikum, Frauenklin, Dusseldorf, Germany
[11] UKSH Campus, Klin Frauenheilkunde & Geburtshilfe, Lubeck, Germany
[12] Frauenarzte Bahnhofspl, Hildesheim, Germany
[13] LMU Campus Grosshadern, Frauenklin, Munich, Germany
[14] Sana Klinikum, Offenbach, Germany
[15] Agaples Markus Krankenhaus, Klin Gynakol & Geburtshilfe, Frankfurt, Germany
[16] Univ Klinikum, Frauenklin, Erlangen, Germany
[17] Sana Klinikum, Frauenklin, Berlin, Germany
[18] Evangel Krankenhaus, Frauenklin, Dusseldorf, Germany
[19] Marien Hosp, Frauenklin, Hamburg, Germany
[20] Hop Hotel Dieu, F-75181 Paris, France
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2014年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：73 / 73
页数：1
相关论文
共 50 条
  • [1] Health-related quality of life (HRQoL) results from the AURELIA trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum-resistant recurrent ovarian cancer (OC)
    Stockler, Martin R.
    Hilpert, Felix
    Friedlander, Michael
    King, Madeleine
    Wenzel, Lari B.
    Lee, Chee
    Joly, Florence
    De Gregorio, Nikolaus
    Arija, Jose Angel Arranz
    Mirza, Mansoor Raza
    Sorio, Roberto
    Freudensprung, Ulrich
    Sneller, Vesna
    Hales, Gill
    lauraine, Eric PujaDe
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC)
    Pujade-Lauraine, Eric
    Hilpert, Felix
    Weber, Beatrice
    Reuss, Alexander
    Poveda, Andres
    Kristensen, Gunnar
    Sorio, Roberto
    Vergote, Ignace B.
    Witteveen, Petronella
    Bamias, Aristotelis
    Pereira, Deolinda
    Wimberger, Pauline
    Oaknin, Ana
    Mirza, Mansoor Raza
    Follana, Philippe
    Bollag, David T.
    Ray-Coquard, Isabelle
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] Bevacizumab (BEV) with or after chemotherapy (CT) for platinum-resistant recurrent ovarian cancer (PROC): Exploratory analyses of the AURELIA trial.
    Bamias, Aristotelis
    Dimopoulos, Meletios A.
    Zagouri, Flora
    Veillard, Anne-Sophie
    Kosse, Jens
    Santaballa, Ana
    Mirza, Mansoor Raza
    Tabaro, Gianna
    Vergote, Ignace
    Bloemendal, Haiko
    Lykka, Maria
    Floquet, Anne
    Lee, Chee
    Gebski, Val
    Pujade-Lauraine, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] Final overall survival (OS) results from AURELIA, an open-label randomised phase III trial of chemotherapy (CT) with or without bevacizumab (BEV) for platinum-resistant recurrent ovarian cancer (OC)
    Witteveen, P.
    Lortholary, A.
    Fehm, T.
    Poveda, A.
    Reuss, A.
    Havsteen, H.
    Raspagliesi, F.
    Vergote, I.
    Bamias, A.
    Pujade-Lauraine, E.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S3 - S4
  • [5] Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial
    Bamias, A.
    Gibbs, E.
    Lee, C. Khoon
    Davies, L.
    Dimopoulos, M.
    Zagouri, F.
    Veillard, A. -S.
    Kosse, J.
    Santaballa, A.
    Mirza, M. R.
    Tabaro, G.
    Vergote, I.
    Bloemendal, H.
    Lykka, M.
    Floquet, A.
    Gebski, V.
    Pujade-Lauraine, E.
    ANNALS OF ONCOLOGY, 2017, 28 (08) : 1842 - 1848
  • [6] Independent radiologic review of AURELIA, a phase 3 trial of bevacizumab plus chemotherapy for platinum-resistant recurrent ovarian cancer
    Husain, Amreen
    Wang, Yan
    Hanker, Lars C.
    Ojeda, Belen
    Anttila, Maarit
    Breda, Enrico
    Vuylsteke, Peter
    Pujade-Lauraine, Eric
    GYNECOLOGIC ONCOLOGY, 2016, 142 (03) : 465 - 470
  • [7] Bevacizumab combined with chemotherapy in platinum-resistant ovarian cancer: beyond the AURELIA trial
    Lyon, Kristopher A.
    Huang, Jason H.
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (04) : 2164 - 2167
  • [8] Combination of Bevacizumab and Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: Some Observations About the AURELIA Trial
    Tomao, Federica
    Tomao, Silverio
    Panici, Pierluigi Benedetti
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (31) : 3580 - 3580
  • [9] Independent radiologic review of AURELIA, a phase 3 trial of bevacizumab (BV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC).
    Husain, Amreen
    Wang, Yan V.
    Frederiksen, Rikke
    Bollag, David T.
    Hanker, Lars Christian
    Ojeda, Belen
    Anttila, Maarit
    Breda, Enrico
    Vuylsteke, Peter
    Pujade-Lauraine, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [10] Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial
    Wysham, Weiya Z.
    Schaffer, Elisabeth M.
    Coles, Theresa
    Roque, Dario R.
    Wheeler, Stephanie B.
    Kim, Kenneth H.
    GYNECOLOGIC ONCOLOGY, 2017, 145 (02) : 340 - 345
12345